Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 4Gastritis, Atrophic 2Stomach Ulcer 1Gastrointestinal Hemorrhage 1Gastrointestinal Diseases 1Gastritis 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Barrett Esophagus 1Adenomatous Polyposis Coli 1Adenocarcinoma Of Esophagus 1

Interventions

Nivolumab 11Oxaliplatin 6Fluorouracil 6Capecitabine 5pembrolizumab 4Paclitaxel 4Leucovorin 4durvalumab 3Radiotherapy 3Folfox protocol 3Drug Therapy 3dehydroftorafur 2Trastuzumab 2Specimen Handling 2Radiation 2Metformin 2Magnetic Resonance Spectroscopy 2Itraconazole 2Irinotecan 2Docetaxel 2Cisplatin 2Carboplatin 2zolbetuximab 1zanidatamab 1trifluridine tipiracil drug combination 1tremelimumab 1trastuzumab deruxtecan 1toripalimab 1tislelizumab 1pertuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Adenocarcinoma Of Esophagus × Gastroscopy × Clear all
NCT04939051 2026-05-13

Obeticholic Acid for Prevention in Barrett's Esophagus

National Cancer Institute (NCI)

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡